Who is at risk for TB?
It is estimated that up to 10% of people infected with M. tuberculosis will develop active tuberculosis (TB) in their lifetime. About one-quarter of the world’s population has a TB infection. The vast majority have no signs or symptoms of TB disease and are not infectious, although they are at risk of developing active TB disease and becoming infectious.
-
Long-term care
About 14 million adults in the United States need long-term care, and over half (56%) are older adults aged 65 and over. These adults living in long-term care facilities have higher rates of TB disease than those living in the community. Screening for latent TB infection in these facilities is critical to prevent the spread of TB.
-
Diabetes
Diabetes is increasingly being recognized as an independent risk factor for TB. Someone with untreated latent TB infection and diabetes is more likely to develop TB disease than someone without diabetes. See how the development of TB in diabetes patients can be prevented by actively testing and treating LTBI.
-
Pediatrics
Once infected with the TB bacteria, children with vulnerable immune systems are most at risk of progressing to active TB disease. TB is preventable, yet over 1.1 million children become ill with it every year. Find out how we can protect children from TB.
-
Healthcare Personnel
Healthcare personnel are at increased risk of tuberculosis infection compared to the general population. How can we protect them and patients in healthcare settings from TB? Learn about TB screening and testing guidelines recommended in healthcare settings for TB control.
-
Student Health
Campuses are highly crowded places with the potential for close contact. Therefore, the risks of TB are amplified. How can you make sure your students and faculty are safe from TB? Check out the preferred TB test for college and updated student health TB screening guidance.
-
Long-term care
-
Diabetes
-
Pediatrics
-
Healthcare Personnel
-
Student Health
The CDC is calling out a testing gap. Can we defuse the TB timebomb?
According to a new study published in the CDC’s Morbidity and Mortality Weekly Report, reported TB incidence (cases per 100,000 persons) increased 9.4%, from 2.2 during 2020 to 2.4 during 2021 but was lower than incidence during 2019 (2.7) (2).
Factors contributing to changes in reported TB during 2020–2021 likely include an actual reduction in TB incidence, delayed or missed TB diagnoses and disruptions in healthcare access (3).
The authors warn that continuing underdiagnosis of TB in the U.S. may derail efforts to eliminate the disease, highlighting the importance of evaluation and treatment of latent tuberculosis infection (LTBI) to prevent progression to TB disease.
How can we get U.S. testing back on track?
Contact us
References:
- Centers for Disease Control and Prevention. Testing for Tuberculosis (TB) factsheet. https://www.cdc.gov/tb/publications/factsheets/testing/tb_testing.htm (accessed October 6, 2021)
- Filardo T.D., Feng P., Pratt R.H., Price S.F., Self J.L. (2021) Tuberculosis — United States. MMWR Morb Mortal Wkly Rep 2022;7 1:441, 446.
- Centers for Disease Control and Prevention. Trends in Tuberculosis, 2020. https://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends.htm (accessed April 7, 2022)
- Centers for Disease Control and Prevention. CDC FACT SHEET: TB in the United States, 2021. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/TB-in-the-US-508.pdf
QFT -Plus is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts, available in multiple languages, as well as up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.
The performance of the USA format of the QFT test has not been extensively evaluated with specimens from individuals who have impaired or altered immune functions, such as those who have HIV infection or AIDS, those who have transplantation managed with immunosuppressive treatment or others who receive immunosuppressive drugs (e.g., corticosteroids, methotrexate, azathioprine, cancer chemotherapy) or in individuals younger than age 17 years.